The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors

Basit Öğe Kaydı
dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390en_US
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021en_US
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorAktepe, Oktay Halit
dc.contributor.authorAksun, Melek Seren
dc.contributor.authorŞahin , Taha Koray
dc.contributor.authorKavgacı, Gözde
dc.contributor.authorÜçgül, Enes
dc.contributor.authorÇakır, İbrahim Yahya
dc.contributor.authorYıldırım, Hasan Çağrı
dc.contributor.authorGüner, Gürkan
dc.contributor.authorAkın, Serkan
dc.contributor.authorKertmen, Neyran
dc.contributor.authorDizdar, Ömer
dc.contributor.authorAksoy, Sercan
dc.contributor.authorErman, Mustafa
dc.contributor.authorSuayib, Yalçın
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2022-06-07T08:15:42Z
dc.date.available2022-06-07T08:15:42Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBACKGROUND: The albumin-globulin ratio (AGR) could be a prognostic biomarker in patients with cancer, although the data is limited in patients treated with immune-checkpoint inhibitors (ICIs). OBJECTIVES: We aimed to evaluate the association between AGR and survival in ICI-treated patients. METHODS: The data of 212 advanced-stage patients were retrospectively evaluated in this cohort study. The association between AGR with overall (OS) and progression-free survival (PFS) were evaluated with multivariate analyses. Additionally, receptor operating curve (ROC) analysis was conducted to assess the AGR’s predictive power in the very early progression (progression within two months) and long-term benefit (more than twelve months survival). RESULTS: The median AGR was calculated as 1.21, and patients were classified into AGR-low and high subgroups according to the median. In the multivariate analyses, patients with lower AGR (< 1.21) had decreased OS (HR: 1.530, 95% CI: 1.100–2.127, p= 0.011) and PFS (HR: 1.390, 95% CI: 1.020–1.895, p= 0.037). The area under curve of AGR to detect early progression and long-term benefit were 0.654 (95% CI: 0.562–0.747, p= 0.001) and 0.671 (95% CI: 0.598–0.744, p< 0.001), respectively. CONCLUSIONS: In our experience, survival with ICIs was impaired in patients with lower AGR. Additionally, the AGR values could detect the very early progression and long-term benefit ICIs.en_US
dc.identifier.citationGuven DC, Aktepe OH, Aksun MS, Sahin TK, Kavgaci G, Ucgul E, Cakir IY, Yildirim HC, Guner G, Akin S, Kertmen N, Dizdar O, Aksoy S, Erman M, Yalcin S, Kilickap S. The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors. Cancer Biomark. 2022;34(2):189-199. doi: 10.3233/CBM-210349. PMID: 34958005.en_US
dc.identifier.doi10.3233/CBM-210349en_US
dc.identifier.endpage199en_US
dc.identifier.issn1574-0153en_US
dc.identifier.issue2en_US
dc.identifier.pmid34958005en_US
dc.identifier.scopus2-s2.0-85130963184en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage189en_US
dc.identifier.urihttp://doi.org/ 10.3233/CBM-210349
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2823
dc.identifier.volume34en_US
dc.identifier.wosWOS:000800580800003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherIOS Pressen_US
dc.relation.ispartofCancer Biomarkers: Section-A of Disease Markersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmune Checkpoint Inhibitoren_US
dc.subjectAlbumin-Globulin Ratioen_US
dc.subjectBiomarkeren_US
dc.subjectImmunotherapyen_US
dc.titleThe association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitorsen_US
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu